We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Erlotinib Warning.
- Abstract
The article reports that the U.S. Food and Drug Administration (FDA) is alerting physicians to the new safety warnings on the label of erlotinib used for treating certain patients with lung or pancreatic cancer, concerning the severe gastrointestinal tract, skin and ocular disorders that can be experienced by patients taking the drug. Letters were also issued by its manufacturers OSI Pharmaceuticals and Genentech to physicians about the adverse effects. The letters noted reports of skin conditions such as bullous and blistering.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; PHYSICIANS; CANCER patients; ANTINEOPLASTIC agents; DRUG side effects; OSI Pharmaceuticals Inc.
- Publication
JAMA: Journal of the American Medical Association, 2009, Vol 301, Issue 24, p2542
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2009.859